GLPwatch

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice

NCT04878393 · Completed

Last updated 2026-05-28

This study is testing how well an oral diabetes medication called semaglutide works in lowering blood sugar levels in adults with type 2 diabetes in Japan as part of routine medical care.

Status Completed The study has finished.
Type Observational
Participants 650 people
Who can join all sexes
Timeline Started 2021-04 · est. completion 2023-02
Where 1 site · Japan

What this study is testing ClinicalTrials.gov NCT04878393 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels, and to get side-effects information. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.

Treatments tested

Main thing measuredChange in glycated haemoglobin (HbA1c)
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04878393 ↗